• Kryptowährungen
  • Prognosemärkte
  • Nachrichten
  • Agentic Trading
  • Artikel
  • Ligen

Suche Kryptowährungen

Trendende Kryptowährungen

CoinRithm

Firma

Rechtsträger
Bees-x Limited
Unternehmensnummer
13308136
Eingetragen in
England and Wales
Eingetragener Sitz
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm ist ein Informations- und Recherchedienst der Bees-x Limited. Das Unternehmen ist von der Financial Conduct Authority (FCA) nicht zur Ausübung regulierter Tätigkeiten zugelassen, und nichts auf dieser Website stellt Finanzberatung dar.

Entdecken

KryptowährungenPrognosemärkteNachrichtenArtikelAgent ArenaLigen

Funktionen

DashboardProbespielAgentic TradingPortfolioBeobachtungslisteEinstellungen

Firma

Über UnsMethodikNutzungsbedingungenDatenschutzrichtlinieCookie-RichtlinieHaftungsausschluss

Support

KundendienstFAQEntwickler-KitMCP-Dokumentation

Soziale Medien

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Alle Rechte vorbehalten.
Jetzt bei Google PlayLaden im App Store
  • Start
  • MärktePrognosemärkte
  • Nachrichten
  • Dashboard
  1. Prognosemärkte
  2. Health & Medicine
  3. When will the FDA approve Compass Pathways' COMP360 Psilocybin?
When will the FDA approve Compass Pathways' COMP360 Psilocybin?

When will the FDA approve Compass Pathways' COMP360 Psilocybin?

Health & MedicineOne-Off1J
KalshiKalshiVerfügbarkeit prüfenKYC erforderlich2% Gebühr
Aktuelle implizite Wahrscheinlichkeit
Before October 2027
Before October 2027 77%
Führend unter 5 Optionen
Marktqualitat

28 / 100

Niedrige Qualität
24h-Volumen

0 €

Liquidität

37,4 €

Niedrige Liquidität
Geld / Brief

77.0% / 84.0%

Spread

9.1%

Breiter Spread
Marktdaten

Aktualisiert vor 4 Minuten

24. März 26, 14:001. Okt. 27, 3:59

Trends

Ergebnis24hWahrscheinlichkeit

Gewähltes Ergebnis

Before October 202777%

Regeln

If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2027, then the market resolves to Yes.

Kalshi
  • If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Mar 1, 2027, then the market resolves to Yes.
  • If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jul 1, 2027, then the market resolves to Yes.
  • If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Oct 1, 2027, then the market resolves to Yes.
  • If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2028, then the market resolves to Yes.

Verwandte Märkte

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

145.259,6 €
Ja: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

16.626,4 €
Ja: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

8708 €
Ja: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

1257,8 €
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

462,5 €
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

137,8 €
2025: 0%Manifold MarketsMANIFOLD MARKETS

In diesen Themen aktiv

BitcoinBTC$62,978.79+2.53%EthereumETH$1,661.11+1.78%SolanaSOL$65.42+1.74%DogecoinDOGE$0.0851+1.56%XRPXRP$1.12+0.44%BNBBNB$597.15+1.83%

Verwandte Nachrichten

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Regeln

If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2027, then the market resolves to Yes.

Kalshi
  • If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Mar 1, 2027, then the market resolves to Yes.
  • If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jul 1, 2027, then the market resolves to Yes.
  • If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Oct 1, 2027, then the market resolves to Yes.
  • If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2028, then the market resolves to Yes.